@article{BousquetOnoratoBachertetal.2017,
  author    = {Bousquet, J. and Onorato, G. L. and Bachert, C. and Barbolini, M. and Bedbrook, A. and Bjermer, L. and Correia de Sousa, J. and Chavannes, N. H. and Cruz, A. A. and De Manuel Keenoy, E. and Devillier, P. and Fonseca, J. and Hun, S. and Kostka, T. and Hellings, P. W. and Illario, M. and Ivancevich, J. C. and Larenas-Linnemann, D. and Millot-Keurinck, J. and Ryan, D. and Samolinski, B. and Sheikh, A. and Yorgancioglu, A. and Agache, I. and Arnavielhe, S. and Bewick, M. and Annesi-Maesano, I. and Anto, J. M. and Bergmann, K. C. and Bindslev-Jensen, C. and Bosnic-Anticevich, S. and Bouchard, J. and Caimmi, D. P. and Camargos, P. and Canonica, G. W. and Cardona, V. and Carriazo, A. M. and Cingi, C. and Cogan, E. and Custovic, A. and Dahl, R. and Demoly, P. and De Vries, G. and Fokkens, W. J. and Fontaine, J. F. and Gemicioğlu, B. and Guldemond, N. and Gutter, Z. and Haahtela, T. and Hellqvist-Dahl, B. and Jares, E. and Joos, G. and Just, J. and Khaltaev, N. and Keil, T. and Klimek, L. and Kowalski, M. L. and Kull, I. and Kuna, P. and Kvedariene, V. and Laune, D. and Louis, R. and Magnan, A. and Malva, J. and Mathieu-Dupas, E. and Mel{\´e}n, E. and Menditto, E. and Morais-Almeida, M. and M{\"o}sges, R. and Mullol, J. and Murray, R. and Neffen, H. and O'Hehir, R. and Palkonen, S. and Papadopoulos, N. G. and Passalacqua, G. and P{\´e}pin, J. L. and Portejoie, F. and Price, D. and Pugin, B. and Raciborski, F. and Simons, F. E. R. and Sova, M. and Spranger, O. and Stellato, C. and Todo Bom, A. and Tomazic, P. V. and Triggiani, M. and Valero, A. and Valovirta, E. and VandenPlas, O. and Valiulis, A. and van Eerd, M. and Ventura, M. T. and Wickmann, M. and Young, I. and Zuberbier, T. and Zurkuhlen, A. and Senn, A.},
  title     = {CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report},
  series = {Clinical and Translational Allergy},
  volume    = {2017},
  journal   = {Clinical and Translational Allergy},
  number    = {7},
  doi       = {10.1186/s13601-017-0173-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173527},
  year      = {2017},
  abstract  = {A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75\% was observed for 14 items (50\%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices.},
  language  = {en}
}
@article{TriphanJobstAnjorinetal.2017,
  author    = {Triphan, Simon M. F. and Jobst, Bertram J. and Anjorin, Angela and Sedlaczek, Oliver and Wolf, Ursula and Terekhov, Maxim and Hoffmann, Christian and Ley, Sebastian and D{\"u}ber, Christoph and Biederer, J{\"u}rgen and Kauczor, Hans-Ulrich and Jakob, Peter M. and Wielp{\"u}tz, Mark O.},
  title     = {Reproducibility and comparison of oxygen-enhanced T\(_1\) quantification in COPD and asthma patients},
  series = {PLoS ONE},
  volume    = {12},
  journal   = {PLoS ONE},
  number    = {2},
  doi       = {10.1371/journal.pone.0172479},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-171833},
  year      = {2017},
  abstract  = {T\(_1\) maps have been shown to yield useful diagnostic information on lung function in patients with chronic obstructive pulmonary disease (COPD) and asthma, both for native T\(_1\) and ΔT\(_1\), the relative reduction while breathing pure oxygen. As parameter quantification is particularly interesting for longitudinal studies, the purpose of this work was both to examine the reproducibility of lung T\(_1\) mapping and to compare T\(_1\) found in COPD and asthma patients using IRSnapShotFLASH embedded in a full MRI protocol. 12 asthma and 12 COPD patients (site 1) and further 15 COPD patients (site 2) were examined on two consecutive days. In each patient, T\(_1\) maps were acquired in 8 single breath-hold slices, breathing first room air, then pure oxygen. Maps were partitioned into 12 regions each to calculate average values. In asthma patients, the average T\(_{1,RA}\) = 1206ms (room air) was reduced to T\(_{1,O2}\) = 1141ms under oxygen conditions (ΔT\(_1\) = 5.3\%, p < 5⋅10\(^{-4})\), while in COPD patients both native T\(_{1,RA}\) = 1125ms was significantly shorter (p < 10\(^{-3})\) and the relative reduction to T\(_{1,O2}\) = 1081ms on average ΔT\(_1\) = 4.2\%(p < 10\(^{-5}\)). On the second day, with T\(_{1,RA}\) = 1186ms in asthma and T\(_{1,RA}\) = 1097ms in COPD, observed values were slightly shorter on average in all patient groups. ΔT\(_1\) reduction was the least repeatable parameter and varied from day to day by up to 23\% in individual asthma and 30\% in COPD patients. While for both patient groups T\(_1\) was below the values reported for healthy subjects, the T\(_1\) and ΔT\(_1\) found in asthmatics lies between that of the COPD group and reported values for healthy subjects, suggesting a higher blood volume fraction and better ventilation. However, it could be demonstrated that lung T\(_1\) quantification is subject to notable inter-examination variability, which here can be attributed both to remaining contrast agent from the previous day and the increased dependency of lung T\(_1\) on perfusion and thus current lung state.},
  language  = {en}
}
@article{FroehlichPinartKelleretal.2017,
  author    = {Fr{\"o}hlich, M. and Pinart, M. and Keller, T. and Reich, A. and Cabieses, B. and Hohmann, C. and Postma, D. S. and Bousquet, J. and Ant{\´o}, J. M. and Keil, T. and Roll, S.},
  title     = {Is there a sex-shift in prevalence of allergic rhinitis and comorbid asthma from childhood to adulthood? A meta-analysis},
  series = {Clinical and Translational Allergy},
  volume    = {7},
  journal   = {Clinical and Translational Allergy},
  doi       = {10.1186/s13601-017-0176-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-172508},
  year      = {2017},
  abstract  = {Background: Allergic rhinitis and asthma as single entities affect more boys than girls in childhood but more females in adulthood. However, it is unclear if this prevalence sex-shift also occurs in allergic rhinitis and concurrent asthma. Thus, our aim was to compare sex-specifc differences in the prevalence of coexisting allergic rhinitis and asthma in childhood, adolescence and adulthood. Methods: Post-hoc analysis of systematic review with meta-analysis concerning sex-specific prevalence of allergic rhinitis. Using random-effects meta-analysis, we assessed male-female ratios for coexisting allergic rhinitis and asthma in children (0-10 years), adolescents (11-17) and adults (> 17). Electronic searches were performed using MEDLINE and EMBASE for the time period 2000-2014. We included population-based observational studies, reporting coexisting allergic rhinitis and asthma as outcome stratifed by sex. We excluded non-original or non-population-based studies, studies with only male or female participants or selective patient collectives. Results: From a total of 6539 citations, 10 studies with a total of 93,483 participants met the inclusion criteria. The male-female ratios (95\% CI) for coexisting allergic rhinitis and asthma were 1.65 (1.52; 1.78) in children (N = 6 studies), 0.61 (0.51; 0.72) in adolescents (N = 2) and 1.03 (0.79; 1.35) in adults (N = 2). Male-female ratios for allergic rhinitis only were 1.25 (1.19; 1.32, N = 5) in children, 0.80 (0.71; 0.89, N = 2) in adolescents and 0.98 (0.74; 1.30, N = 2) in adults, respectively. Conclusions: The prevalence of coexisting allergic rhinitis and asthma shows a clear male predominance in childhood and seems to switch to a female predominance in adolescents. This switch was less pronounced for allergic rhinitis only.},
  language  = {en}
}
@article{GarciaLarsenArthurPottsetal.2017,
  author    = {Garcia-Larsen, Vanessa and Arthur, Rhonda and Potts, James F. and Howarth, Peter H. and Ahlstr{\"o}m, Matti and Haahtela, Tari and Loureiro, Carlos and Bom, Ana Todo and Brożek, Grzegorz and Makowska, Joanna and Kowalski, Marek L. and Thilsing, Trine and Keil, Thomas and Matricardi, Paolo M. and Tor{\´e}n, Kjell and van Zele, Thibaut and Bachert, Claus and Rymarczyk, Barbara and Janson, Christer and Forsberg, Bertil and Niżankowska-Mogilnicka, Ewa and Burney, Peter G. J.},
  title     = {Is fruit and vegetable intake associated with asthma or chronic rhino-sinusitis in European adults? Results from the Global Allergy and Asthma Network of Excellence (GA\(^2\)LEN) Survey},
  series = {Clinical and Translational Allergy},
  volume    = {7},
  journal   = {Clinical and Translational Allergy},
  doi       = {10.1186/s13601-016-0140-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-180887},
  pages     = {9},
  year      = {2017},
  abstract  = {Background: Fruits and vegetables are rich in compounds with proposed antioxidant, anti-allergic and anti-inflammatory properties, which could contribute to reduce the prevalence of asthma and allergic diseases. Objective: We investigated the association between asthma, and chronic rhino-sinusitis (CRS) with intake of fruits and vegetables in European adults. Methods: A stratified random sample was drawn from the Global Allergy and Asthma Network of Excellence (GA\(^2\)LEN) screening survey, in which 55,000 adults aged 15-75 answered a questionnaire on respiratory symptoms. Asthma score (derived from self-reported asthma symptoms) and CRS were the outcomes of interest. Dietary intake of 22 subgroups of fruits and vegetables was ascertained using the internationally validated GA\(^2\)LEN Food Frequency Questionnaire. Adjusted associations were examined with negative binomial and multiple regressions. Simes procedure was used to control for multiple testing. Results: A total of 3206 individuals had valid data on asthma and dietary exposures of interest. 22.8\% reported having at least 1 asthma symptom (asthma score ≥1), whilst 19.5\% had CRS. After adjustment for potential confounders, asthma score was negatively associated with intake of dried fruits (β-coefficient -2.34; 95\% confidence interval [CI] -4.09, -0.59), whilst CRS was statistically negatively associated with total intake of fruits (OR 0.73; 95\% CI 0.55, 0.97). Conversely, a positive association was observed between asthma score and alliums vegetables (adjusted β-coefficient 0.23; 95\% CI 0.06, 0.40). None of these associations remained statistically significant after controlling for multiple testing. Conclusion and clinical relevance: There was no consistent evidence for an association of asthma or CRS with fruit and vegetable intake in this representative sample of European adults.},
  language  = {en}
}
@phdthesis{Duechs2011,
  author    = {D{\"u}chs, Matthias},
  title     = {Effects of Toll-like receptor agonists on the pathogenesis of atopic asthma in mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-66369},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {In the last decades, both the incidence and the severity of asthma have steadily increased. Furthermore, available therapies only treat the symptoms but do not cure the disease. Immune modulation induced by TLR agonists may be a promising novel approach to effectively treat asthma as it targets the underlying immunopathology directly rather than one mediator alone. The aim of this thesis was to investigate if the immunostimulatory properties of Toll-like receptor (TLR) agonists can be utilized to develop novel therapeutic intervention strategies for the treatment of asthma using murine models of allergic inflammation. For this purpose five different TLR agonists were tested in preclinical mouse models of acute and chronic asthma, both in preventive and therapeutic settings. Firstly, TLR-2, 3, 4, 7/8 and 9 agonists were delivered intratracheally at different doses before pulmonary allergen exposure in the asthma model of acute inflammation. TLR9 agonist CpG-containing oligodeoxynucleotides (CpG) > TLR7 agonist Resiquimod (R848) > TLR3 agonists poly(I:C) strongly reduced allergen induced airway eosinophilia and IL-4 levels in a dose-dependent manner. All TLR agonists increased neutrophil numbers, TLR4 agonist lipopolysaccharide (LPS) > TLR2 agonist lipoteichonic acid (LTA) > poly(I:C) > CpG > R848 and, with the exception of R848, the amount of pro-inflammatory cytokines in the airways. Suppressive effects were not dependent upon IFN-γ and IL-10 or associated with increased numbers of regulatory T cells in the airways. All TLR agonists, except LTA, similarly reduced airway eosinophilia and IL-4 levels when applied therapeutically after allergen challenge. These results show that the TLR agonists have different suppressive effects on TH2 responses in the airways which further depend on the dose and the experimental setup in which they were tested. Interestingly, all agonists induced airway neutrophilia, albeit to different degrees, raising the question if TLR ligands are safe for human use when applied directly into the lung. Different TLR agonists are also being developed for human use as adjuvants combined with allergen in specific immunotherapy. Recent clinical data suggest that this may be achieved by induction of allergen-specific TH1 responses. For this reason, the ability of different TLR agonists to induce allergen-specific TH1 and suppress allergen-specific TH2 responses in a preclinical setting was investigated in this thesis. Different doses of the TLR agonists were applied together with allergen, then mice were exposed to allergen aerosol. CpG > LPS >LTA dose-dependently strongly suppressed the development of airway eosinophilia with poly(I:C) and R848 having no effect. The decrease in eosinophilic numbers was associated withincreased neutrophils present in the airways. IL-4 and IL-5 levels in the bronchoalveolar lavage fluid were also decreased when poly(I:C), LPS, and CpG were used. All TLR agonists increased allergen-specific IgG2a, and with the exception of poly(I:C), reduced allergen-specific IgE levels in the serum. Cutaneous anaphylaxis to allergen was completely prevented when LPS or CpG were given as adjuvant. The strongest TH1 responses were induced by CpG and poly(I:C), characterized by the presence of IFN-γ in the bronchoalveolar lavage and the highest allergen-specific IgG2a levels in the serum. This data supports approaches to use TLR9 or TLR4 agonists for human therapy as adjuvant in combination with allergen in novel specific immunotherapy formulations. In the last part of the thesis, it was investigated if TLR activation can also affect the pathology of severe chronic asthma. Therapeutic administration of R848 or CpG reduced features of inflammation and remodeling. Both agonists showed superior effects to dexamethasone, with CpG being more efficient than R848. This result again supports a TLR9-based therapy as a viable option for the treatment of severe chronic asthma which may present a potential alternative for anti-inflammatory therapy with steroids. Taken together, the results of this thesis support the use of TLR agonists to treat asthma. The most favorable efficacy/safety ratio is to be expected from TLR-based therapies combining TLR4 or TLR9 agonists with allergen in specific immunotherapy. In regard to TLR agonist monotherapy, R848 and CpG showed the most promising profiles, CpG particularly in a model of severe chronic asthma. However, since all TLR agonists used in this study also showed pro-inflammatory potential, the safety aspect of such an approach needs to be taken into account.},
  subject      = {Toll-like Rezeptor},
  language  = {en}
}
@phdthesis{TrujilloVargas2005,
  author    = {Trujillo Vargas, Claudia Milena},
  title     = {Development of vaccines against allergic asthma using products derived from intracellular bacteria or helminths},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-12992},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {Die „Hygiene Hypothese" postuliert, dass der Kontakt mit Infektionserregern in der fr{\"u}hen Kindheit die Entwicklung von Th2-abh{\"a}ngigen allergischen Immunreaktionen verhindern kann, indem dadurch entweder eine vorrangig Th1-gerichtete Immunit{\"a}t etabliert wird oder alternativ die Bildung von regulatorischen T Zellen induziert wird. Basierend auf dieser Theorie zielte die vorliegende Arbeit darauf ab, Produkte von Mikroorganismen oder W{\"u}rmern als m{\"o}gliche Komponenten von Impfstoffen gegen Allergien zu testen. Im ersten Teil dieser Arbeit wurden lebende BCG, Hitze abget{\"o}tete BCG (hk-BCG), CpG und PPD, die alle als Th1 Adjuvantien bekannt sind, auf ihre Effektivit{\"a}t getestet, allergisches Asthma in der Maus zu unterdr{\"u}cken. Alle Adjuvantien konnten die durch Allergie induzierte Lungeneosinophilie, die Schleimproduktion in der Lunge und mit Ausnahme von PPD, die Lungen{\"u}berempfindlichkeit (AHR) unterdr{\"u}cken, wenn sie zusammen mit OVA/alum verabreicht wurden. Die Lungeneosinophilie konnte jedoch nicht in IL-12 oder IFN-gamma defizienten M{\"a}usen durch die Applikation von hk-BCG, CpG oder PPD verhindert werden. Interessanterweise waren jedoch lebende BCG in der Lage, die allergische Th2 Immunreaktion zu unterdr{\"u}cken. Ebenso war die Wirkung von lebendem BCG unabh{\"a}ngig vom IL-10, TLR-2, TLR-4 oder MyD88 vermittelten Signalweg. Wurden M{\"a}use, die mit den verschiedenen Adjuvantien zusammen mit OVA/alum geimpft wurden, einer zweiten Runde OVA/alum Sensibilisierung unterzogen, so konnten nur lebende und hk-BCG die Entwicklung der Entz{\"u}ndung in der Lunge effektiv unterdr{\"u}cken. Diese Wirkung konnte durch den adoptiven Transfer von CD4+ T Zellen auf naive M{\"a}use {\"u}bertragen werden. Zusammenfassend zeigen diese Daten, daß lebende BCG am effektivsten, gefolgt von hk-BCG, CpG und schließlich PPD allergische Th2 Immunreaktionen unterdr{\"u}cken konnten. Als n{\"a}chstes wurde untersucht, ob eine Impfung mit dendritischen Zellen (DC) die Entwicklung von Th2 Zellen durch die Induktion von allergenspezifischen Th1 Zellen verhindern kann. Die Applikation von OVA-gepulsten aus dem Knochenmark stammenden-dendritischen Zellen (BM-DC), die mit CpG in vitro stimuliert wurden, konnten die Lungeneosinophilie und Entz{\"u}ndung in den Atemwegen in OVA-immunisierten M{\"a}usen nicht reduzieren. OVA-spezifische IgG1 und IgE Antik{\"o}rpermengen im Serum waren ebenfalls nicht vermindert. Versuche mit OVA-gepulsten Langerhans-zellen (LC) f{\"u}hrten zu {\"a}hnlichen Ergebnissen wie mit BM-DC. Jedoch waren in M{\"a}usen, die mit CpG/OVA gepulsten BM-DC behandelt wurden, deutlich erh{\"o}hte Werte an OVA-spezifischen IgG2a Antik{\"o}rper im Serum nachzuweisen, was auf die Induktion einer allergenspezifischen Th1 Immunreaktion in vivo schließen l{\"a}ßt. Insgesamt zeigen die Ergebnisse aber, dass weder die Impfung mit OVA-gepulsten und CpG-stimulierten BM-DC noch mit OVA-gepulsten LC eine Verringerung der allergischen Th2 Immunreaktion in einem Mausmodell mit schwerem atopischem Asthma bewirkt. Im dritten Teil der Arbeit wurde NES, ein exkretorisches/sekretorisches Produkt des Helminthen Nippostrongylus brasiliensis, als ein neues m{\"o}gliches Adjuvant zur Unterdr{\"u}ckung allergischer Reaktionen untersucht. Die Applikation von NES zusammen mit OVA/alum inhibierte deutlich die Entwicklung der Lungeneosinophilie, Becherzellmetaplasie und Schleimproduktion in der Lunge sowie die Entwicklung der AHR. Das verwendete NES enthielt geringe Mengen an LPS, die diese Wirkung erkl{\"a}ren k{\"o}nnte. Allerdings war die Unterdr{\"u}ckung der Th2 Immunreaktion durch NES unabh{\"a}ngig von TLR-4 und konnte immer noch nachgewiesen werden, wenn LPS-depletiertes NES verwendet wurde. Schließlich konnte NES die OVA-induzierte Th2 Immunreaktion unabh{\"a}ngig von IL-10 und IFN-gamma reduzieren. Außerdem konnte der Verdau von NES mit Proteinase K oder eine Hitzebehandlung (kochen) den Th2-unterdr{\"u}ckenden Effekt nicht aufheben. Interessanterweise inhibierte NES in vivo eine OVA-spezifische Th2 Immunreaktion in Anwesenheit einer starken NES-spezifischen Th2 Reaktion. Zusammenfassend f{\"u}hren diese Ergebnisse zu dem Schluß, daß der Helminth N. brasiliensis Substanzen produziert, die die Entwicklung von allergischen Th2 Immunreaktionen beeinflussen. Diese Produkte und ihre Wirkmechanismen genauer zu charakterisieren, k{\"o}nnte zu sehr effektiven Adjuvantien f{\"u}hren, welche allergische Reaktionen unterdr{\"u}cken k{\"o}nnten. Die Ergebnisse dieser Arbeit k{\"o}nnten zuk{\"u}nftig dazu beitragen, effiziente Impfungen zu entwickeln, die Menschen vor der Entwicklung von allergischen Immunreaktionen sch{\"u}tzen.},
  subject      = {Bronchialasthma},
  language  = {en}
}
@phdthesis{Noskov2003,
  author    = {Noskov, Andrey},
  title     = {Structural and functional studies of the Interleukin-5 receptor system},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-8195},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {The aim of current work was contribution to the long-term ongoing project on developing human IL-5 agonists/antagonists that intervene with or inhibit IL-5 numerous functions in cell culture and/or in animal disease models. To facilitate design of an IL-5 antagonist variant or low-molecular weight mimetics only capable of binding to the specific receptor alpha chain, but would lack the ability to attract the receptor common \&\#946;-chain and thus initiate receptor complex activation it is necessary to gain the information on minimal structural and functional epitopes. Such a strategy was successfully adopted in our group on example of Interleukin 4. To precisely localize minimal structural epitope it is essential to have structure of the ligand in its bound form and especially informative would be structure of complex of the ligand and its specific receptor alpha chain. For this purpose large quantities (tens of milligrams), retaining full biological activity IL-5 and extracellular domain of IL-5 specific receptor \&\#945;-chain were expressed in a bacterial expression system (E.coli). After successful refolding proteins were purified to 95-99\% Stable and soluble receptor:ligand complex was prepared. Each established purification and refolding procedures were subjected to optimization targeting maximal yields and purity. Produced receptor:ligand complex was applied to crystallization experiments. Microcrystals were initially obtained with a flexible sparse matrix screening methodology. Crystal quality was subsequently improved by fine-tuning of the crystallization conditions. At this stage crystals of about 800x150x30µm in size can be obtained. They possess desirable visible characteristics of crystals including optical clarity, smooth facecs and sharp edges. Crystals rotate plane polarized light reflecting their well internal organization. Unfortunately relative slimness and sometimes cluster nature of the produced crystals complicates acquisition of high-resolution dataset and resolution of the structure. With some of obtained crystals diffraction to a resolution up to 4{\AA} was observed.},
  subject      = {Interleukin 5},
  language  = {en}
}